Merck Announces Strategic Acquisition of Terns Pharmaceuticals to Bolster Hematology Portfolio

Merck & Co. Inc. has officially announced a definitive agreement to acquire Terns Pharmaceuticals in a transaction valued at approximately $6.7 billion. The strategic move is designed to significantly enhance Merck's hematology pipeline, specifically through the integration of TERN-701, a promising treatment candidate for chronic myeloid leukemia (CML). The acquisition reflects a broader industry trend of major pharmaceutical firms investing in targeted therapies to address complex medical conditions.

The financial structure of the deal includes a purchase price of $53.00 per share, representing a 31% premium over the 60-day average price calculated as of March 24, 2026. Both companies' boards of directors have unanimously approved the transaction, signaling strong internal confidence in the long-term value proposition of the merger. The finalization of the deal remains subject to customary closing conditions, including the requirement that a majority of Terns Pharmaceuticals' stockholders tender their shares.

From a fiscal perspective, Merck anticipates the deal will close in the second quarter of 2026. The company expects to incur a charge of approximately $5.8 billion, or roughly $2.35 per share, which will be reflected in both the second quarter and full-year 2026 financial results. This capital allocation underscores Merck's commitment to maintaining a competitive edge in the global pharmaceutical market through aggressive research and development expansion.

This acquisition aligns with the current administration's focus on fostering an environment conducive to corporate growth and domestic innovation. By streamlining its portfolio and securing advanced therapeutic assets, Merck is positioning itself to continue delivering high-value medical solutions. As the pharmaceutical sector navigates a complex regulatory and economic landscape, such strategic consolidations remain a primary driver of industry advancement and shareholder value.